| Literature DB >> 29371642 |
Mitchell G Thompson1,2,3, Nima Sedaghatian1,2, Jesus F Barajas2,4, Maren Wehrs1,2, Constance B Bailey1,2, Nurgul Kaplan1,2,4, Nathan J Hillson1,2,4, Aindrila Mukhopadhyay1,2, Jay D Keasling5,6,7,8,9.
Abstract
pSC101 is a narrow host range, low-copy plasmid commonly used for genetically manipulating Escherichia coli. As a byproduct of a genetic screen for a more sensitive lactam biosensor, we identified multiple novel mutations that increase the copy number of plasmids with the pSC101 origin. All mutations identified in this study occurred on plasmids which also contained at least one mutation localized to the RepA protein encoded within the origin. Homology modelling predicts that many of these mutations occur within the dimerization interface of RepA. Mutant RepA resulted in plasmid copy numbers between ~31 and ~113 copies/cell, relative to ~5 copies/cell in wild-type pSC101 plasmids. Combining the mutations that were predicted to disrupt multiple contacts on the dimerization interface resulted in copy numbers of ~500 copies/cell, while also attenuating growth in host strains. Fluorescent protein production expressed from an arabinose-inducible promoter on mutant origin derived plasmids did correlate with copy number. Plasmids harboring RepA with one of two mutations, E83K and N99D, resulted in fluorescent protein production similar to that from p15a- (~20 copies/cell) and ColE1- (~31 copies/cell) based plasmids, respectively. The mutant copy number variants retained compatibility with p15a, pBBR, and ColE1 origins of replication. These pSC101 variants may be useful in future metabolic engineering efforts that require medium or high-copy vectors compatible with p15a- and ColE1-based plasmids.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29371642 PMCID: PMC5785507 DOI: 10.1038/s41598-018-20016-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Selection for pMGT1 mutants with greater sensitivity. (A) Checkerboard assay showing growth rate of E. coli harboring pMGT1 challenged with increasing concentrations of tetracycline as a function of increasing concentrations of the inducer caprolactam. (B) Results from plate selections of the mutant pMGT1 library plated on LB agar with 0.1 mM caprolactam and 25 mg/L tetracycline compared to E. coli harboring unmutated parent pMGT1.
Figure 2Distribution of mutants obtained from plate-based selections. Inset: Distribution of locations of mutations within the plasmid pMGT1. Histogram showing the frequency of selected amino acid substitutions found within RepA in re-sequenced plasmids.
Figure 3Homology model of RepA homodimer (shown in blue and gold) based on the RepE structure (shown in gray). (A) Full protein dimer. (B) Zoomed in view of N99 and R46 residues, the two most commonly isolated RepA mutants. (C) Potential electrostatic interaction between residues E93 and K102. (D) Potential electrostatic interaction between residues E115 and R43.
Figure 4Copy number of control plasmids and pSC101 RepA mutants as determined by qPCR. Error bars represent 95% CI (n = 3).
Figure 5Production of RFP as a function of plasmid copy number and inducer concentration. Expression of RFP as measured by fluorescence normalized to OD600 following induction from the araBAD promoter with increasing concentrations of arabinose induction. Error bars represent 95% CI (n = 3). Plasmids are ordered by increasing copy number.
Figure 6Plasmid compatibility of potentially useful pSC101 origin mutants with other commonly used E. coli plasmid origins. pSC101 wt and the E83K and N99D mutants encoded kanamycin resistance, while pBBR and p15a encoded carbenicillin resistance. Ratios of the number of CFUs recovered on Carb/Kan LB plates relative to the number of CFUs recovered on LB Carb alone. Error bars represent 95% CI.
Figure 7Copy number of control plasmids, parent RepA mutations, and double RepA mutations predicted to be involved in electrostatic interactions between monomers, as estimated by qPCR. Error bars represent 95% CI (n = 3).
All strains and plasmids used in this study.
| Strain | Notes | Reference | JBEI ID |
|---|---|---|---|
| Invitrogen | |||
| ∆ |
[ | ||
| Commercial mutator strain | Agilent | ||
|
|
|
| |
| pBbS8k-RFP_R43W | RepA Mutant, Kan | This work | JPUB_009625 |
| pBbS8k-RFP_R46W | RepA Mutant, Kan | This work | JPUB_009627 |
| pBbS8k-RFP_R46Q | RepA Mutant, Kan | This work | JPUB_009629 |
| pBbS8k-RFP_M78I | RepA Mutant, Kan | This work | JPUB_009631 |
| pBbS8k-RFP_E83K | RepA Mutant, Kan | This work | JPUB_009633 |
| pBbS8k-RFP_E93G | RepA Mutant, Kan | This work | JPUB_009635 |
| pBbS8k-RFP_N99D | RepA Mutant, Kan | This work | JPUB_009637 |
| pBbS8k-RFP_N99K | RepA Mutant, Kan | This work | JPUB_009639 |
| pBbS8k-RFP_K102E | RepA Mutant, Kan | This work | JPUB_009641 |
| pBbS8k-RFP_E115K | RepA Mutant, Kan | This work | JPUB_009643 |
| pBbS8k-RFP_R43W_E93G | RepA Double Mutant, Kan | This work | JPUB_009645 |
| pBbS8k-RFP_K102E_E115K | RepA Double Mutant, Kan | This work | JPUB_009647 |
| pBbS8k-RFP | AraC Expression Vector, pSC101 Ori, Kan |
[ | |
| pBbA8k-RFP | AraC Expression Vector, p15a Ori, Kan |
[ | |
| pBbE8k-RFP | AraC Expression Vector, ColE1 Ori, Kan |
[ | |
| pBbE8a-RFP | AraC Expression Vector, ColE1 Ori, Amp |
[ | |
| pBbB8a-RFP | AraC Expression Vector, BBR Ori, Amp |
[ | |
| pBbS8a-RFP | AraC Expression Vector, p15a Ori, Amp |
[ | |
| pMGT1 | ChnR Biosensor with TetA Reporter, pSC101 Ori, Spec | This work | JPUB_009650 |
| pBbSlactamC-mCherry (star) | ChnR Biosensor with mCherry Reporter, pSC101 Ori, Spec |
[ |
Strains and plasmids created in this study can be found at https://public-registry.jbei.org/folders/338.